

Georgia Department of Public Health: GDPH SNF Office Hours August 18, 2023

Meet the Team



Presenters:

Swati Gaur, MD, MBA, CMD, AGSF

HEAI

TH SOLUT

Medical Director, Alliant Health Solutions

Amy Ward, MS, BSN, RN, CIC, FAPIC Patient Safety Manager Alliant Health Solutions



Swati Gaur, MD, MBA, CMD, AGSF

MEDICAL DIRECTOR, POST-ACUTE CARE NORTHEAST GEORGIA HEALTH SYSTEM

Dr. Swati Gaur is the medical director of New Horizons Nursing Facilities with the Northeast Georgia Health System. She is also the CEO of Care Advances Through Technology, a technology innovation company. In addition, Dr. Gaur is on the electronic medical record (EMR) transition and implementation team for the health system, providing direction to EMR entity adaption to the long-term care (LTC) environment. She has also consulted with post-acute longterm care (PALTC) companies on optimizing medical services in PALTC facilities, integrating medical directors and clinicians into the QAPI framework, and creating frameworks of interdisciplinary work in the organization. Dr. Gaur established the palliative care service line at the Northeast Georgia Health System.

She also is an attending physician in several nursing facilities. Dr. Gaur attended medical school in Bhopal, India, and started her residency in internal medicine at St. Luke's–Roosevelt Medical Center in New York. She completed her fellowship in geriatrics at the University of Pittsburgh Medical Center and is board certified in internal medicine, geriatrics, hospice, and palliative medicine. In addition, she earned a master's in business administration at the Georgia Institute of Technology with a concentration in technology management.





Amy Ward, MS, BSN, RN, CIC, FAPIC

PATIENT SAFETY MANAGER

Amy is a registered nurse with a diverse background in acute care nursing, microbiology, epidemiology and infection control. She is passionate about leading and mentoring new and future infection preventionists in their career paths and assisting them in reducing healthcare-associated infections across the continuum of care.

Amy enjoys spending time with her family and being outdoors camping, bicycling and running.

Contact: <u>Amy.Ward@AlliantHealth.org</u>





Thank You to Our Partners

- Georgia Department of Public Health
- University of Georgia





UNIVERSITY OF GEORGIA



Learning Objectives

- Learners will understand COVID-19 data and use it to inform their IP practice.
- Learners will apply the infection prevention risk assessment to day-to-day workflows and improvement activities.
- Learners will apply CDC guidelines to their daily practice.



COVID Data Tracker

Maps, charts, and data provided by CDC, updates Mondays and Thursdays by 8 p.m. ET

COVID-19 Home


Key Data Takeaways (as of 8/7/2023)

• COVID-19 indicators, including <u>hospital admissions</u>, <u>emergency department visits</u>, <u>test positivity</u>, and <u>wastewater levels</u>, are increasing nationally.

• CDC's guidance for individual and community actions around COVID-19 are tied to hospital admission levels, which are currently low for more than 99% of the country.




Wastewater Surveillance



Current virus	Category change in					
evels category			last 7 days			
New Site	141	10	4%			
0% to 19%	282	21	- 26%			
20% to 39%	479	35	- 1%			
40% to 59%	310	23	3%			
60% to 79%	136	10	16%			
80% to 100%	25	2	14%			




Wastewater Change







COVID-19 Hospitalization





ED Admission







Variant Distribution for COVID-19

Weighted and Nowcast Estimates in United States for 2-Week Periods in 4/16/2023 - 8/5/2023


Hover over (or tap in mobile) any lineage of interest to see the amount of କ୍ଥ uncertainty in that lineage's estimate.

	Model-based								USA					
	eighted Estimates: Variant proportions based on projected ported genomic sequencing results estimates of							WHO label	Lineage #	%Total	95%PI			
			,		-		variant		Omicron	EG.5	17.3%	14.1-21.0%		
100%-							_			XBB.1.16	15.6%	12.5-19.2%		
10070							EG.5	10		XBB.2.3	11.2%	9.5-13.1%		
							Ш Ш	EG.5		XBB.1.5	10.3%	8.6-12.3%		
										FL.1.5.1	8.6%	4.2-16.1%		
2 80% 60% 40%										XBB.1.16.6	7.7%	5.6-10.8%		
5			ω	5	XBB.1.5	XBB.1.5	XBB.1.5			XBB.1.16.1	7.2%	6.0-8.7%		
		ιų.		XBB.1.5	8	88	8			XBB.1.9.1	5.4%	4.5-6.5%		
5 60%	12	XBB.1.5	XBB.1.5	~		1	×			XBB.1.9.2	4.8%	3.5-6.6%		
	X88.1.5	8								XBB	4.4%	3.1-6.1%		
	×									XBB.1.5.72	2.4%	1.6-3.7%		
40%							60			XBB.1.5.10	1.2%	0.7-1.9%		
40%							XBB.1.16			FE.1.1	1.1%	0.6-2.1%		
							8			CH.1.1	1.1%	0.6-1.9%		
							×			XBB.1.5.68	0.6%	0.4-1.0%		
20%										XBB.1.5.59	0.4%	0.2-0.8%		
										EU.1.1	0.3%	0.2-0.6%		
				_						XBB.1.5.1	0.2%	0.1-0.2%		
0%										BA.2	0.0%	0.0-0.1%		
	23	23	23	23	23	7/8/23	23	23		BA.2.12.1	0.0%	0.0-0.1%		
	4/29/23	5/13/23	5/27/23	6/10/23	6/24/23	7/8	7122123	8/5/23		FD.2	0.0%	0.0-0.0%		
	ম	43	43	Ð	¢		~			BA.5	0.0%	0.0-0.0%		
								Selected 2-Medk		BQ.1.1	0.0%	0.0-0.0%		
								2.W		BQ.1	0.0%	0.0-0.0%		
			Collection	on date i	two-wee	k period endi	00		Other	Other*	0.1%	0.0-0.1%		

Nowcast Estimates in United States						
for 7/23/2023 – 8/5/2023						



COVID-19 Cases in Nursing Home Residents






COVID-19 Cases in Nursing Home Staff


Confirmed COVID-19 Cases among Staff and Rate per 1,000 Resident-Weeks in Nursing Homes, by Week—United States

CDC Confirmed COVID-19 Cases among Staff and Rate per 1,000 Resident-Weeks in Nursing Homes, by Week — United States







Safety Strategy













Paxlovid

- Creatinine clearance GFR
- Severe hepatic impairment
- Liverpool drug interaction checker



Molnupiravir

• Four capsules bid for five days



CMS Therapeutics Memo

DEPARTMENT OF HEALTH & HUMAN SERVICES Centers for Medicare & Medicaid Services 7500 Security Boulevard, Mail Stop C2-21-16 Baltimore, Maryland 21244-1850



Center for Clinical Standards and Quality

Ref: QSO-23-03-All

- DATE: November 22, 2022
- TO: State Survey Agency Directors
- FROM: Directors, Quality, Safety & Oversight Group (QSOG) and Survey & Operations Group (SOG)
- SUBJECT: The Importance of Timely Use of COVID-19 Therapeutics

Memorandum Summary

- Providers and suppliers, especially those delivering care in congregate care settings, should
 ensure their patients and residents are protected against transmission of COVID-19 within
 their facilities, as well as receiving appropriate treatment when tested positive for the virus.
- Further, all providers and suppliers should continue to implement appropriate infection control protocols for COVID-19 (https://www.cdc.gov/coronavirus/2019-ncov/hcp/infectioncontrol.html) and Influenza (https://www.cdc.gov/flu/professionals/infectioncontrol/index.htm).
- This memo discusses the importance of the timely use of available COVID-19 therapeutics, particularly for high-risk patients who test positive for the virus.

Background

The purpose of this memo is to highlight the importance of providing timely access to available COVID-19 therapeutics to patients who test positive for the virus. Treatments, including both ctioncontrol/index.htm cloal antibodies and oral antiviral drugs, can prevent serious illness and save the lives of



Infection Prevention Risk Assessment

- Infection Prevention Risk assessment should be updated annually and as needed
- After an outbreak investigation, a risk assessment should be updated

INFECTION EVENT	TION EVENT PROBABILITY OF OCCURRENCE (How likely is this to occur?)				LEVEL OF HARM FROM EVENT (What would be the most likely?)					IMPACT ON CARE			READINESS TO PREVENT			RISK LEVEL
									(Will new treatment/care be needed for resident/staff?)			(Are processes/resources in place to identify/address this event?)			(Scores ≥ 8 are considered highest priority for improvement efforts.)	
					Serious	Moderate	Temp.						_			
Score	High 3	Med. 2	Low 1	None 0	Harm 3	Harm 2	Harm 1	None 0	High 3	Med. 2	Low 1	None 0	Poor 3	Fair 2	Good 1	
Facility-onset Infections(s)	•	2	•	U	, v	2	•	v	J	2		v	J. J	2	1	
Outbreak-related																
Influenza*		2				2			3						1	8
Other viral respiratory																
pathogens*	3				3				3				3			12
Norovirus gastroenteritis*		2					1			2			3			8
Bacterial gastroenteritis																
(e.g.,Salmonella, Shigella)			1				1			2			3			7
Scabies																
Conjunctivitis																
Group A Streptococcus*																
MDRO																
Other (specify):																
* Risk assessment should tak																

Actions to Take

- For all high-risk event line items
 - Review the rating by column and understand why the rating was applied
 - Look through each category with a score of 2 or 3 and apply interventions to reduce risk
 - Probability of occurrence
 - Level of harm
 - Impact on care
 - Readiness to prevent





- How can we reduce the likelihood of this event type from occurring?
 - Is there a vaccine available?
 - Is there recommended post-exposure prophylaxis?
 - What are the isolation and quarantine guidelines?
 - What are the visitor and staff screening guidelines?
 - What are the criteria for staff exclusion if ill or exposed?
 - Other recommendations dependent on disease.



- Increase up-to-date vaccination rates for staff and residents to greater than 90% by October 15, 2023.
- Implement a routine process to identify and manage individuals with suspected COVID-19 before entry to the facility.
 - Example visual alerts
- Implement source control measures for the facility when the risk for COVID-19 or other respiratory viral illnesses increases in the community or when recommended by public health authorities.

Ensure these goals and practices are incorporated into policy and procedures for the facility. <u>Infection Control: Severe acute respiratory syndrome</u> <u>coronavirus 2 (SARS-CoV-2) | CDC</u>





- Optimize indoor air quality by ensuring ventilation systems meet health care facility standards for humidity, air changes per hour, filtration and fresh air changes.
- Utilize standard precautions during all activities in health care facilities.

Ensure all goals and practices are incorporated into policy and procedures for the facility and are based on the most up-to-date CDC guidelines: Infection Control: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) | CDC.



- Ensure policies for work restriction, including return-to-work, are updated according to <u>CDC guidelines</u>.
 - Asymptomatic staff who have had higher exposure risk do not generally require work restriction if no symptoms develop or if testing is negative.
 - Staff should follow all IPC practices, including wearing a well-fitting source control mask, self-monitor for fever and symptoms of COVID-19, and not reporting to work when ill or if testing positive for SARS-CoV-2 infection.
 - Prioritize testing for all staff who have any symptoms, even mild ones.
 - One negative PCR test is sufficient in most cases unless there is high clinical suspicion.
 - One negative antigen confirmed by a negative PCR or a second negative antigen 48 hours after the first negative test.
 - Return-to-work decisions should be based on other suspected or confirmed diagnoses, do not consider COVID-19 alone in return-to-work decisions.



Knowledge Check

Nurse Heather was exposed to COVID-19 on Tuesday, 8/15/2023. She is scheduled to work again on Friday, 8/18/2023.

Does Heather need to be tested before she returns to work?

- Yes
- No



Knowledge Check

- Nurse Heather was exposed to COVID-19 on Tuesday 8/15/2023. She is scheduled to work again on Friday, 8/18/2023.
- Does Heather need to be tested before she returns to work?



– No

Key Points

- In general, asymptomatic HCP who have had a higher-risk exposure do not require work restriction, regardless of vaccination status, if they do not develop symptoms or test positive for SARS-CoV-2.
- When the risk for COVID-19 is high (increasing ED visits, hospitalizations, etc.), the facility should consider utilizing testing to guide return to work.
- Staff should follow all IPC practices, including wearing a well-fitting source control mask, selfmonitor for fever and symptoms of COVID-19, and not reporting to work when ill or if testing positive for SARS-CoV-2 infection.



- Positive symptomatic staff who are not immunocompromised
 - Mild to moderate illness and not immunocompromised
 - At least seven days have passed since symptom onset and a negative viral test obtained at least 48 hours before return to work, and no fever within 24 hours, symptoms improving (if antigen test used to test at day five post symptom onset and 48 hours before return to work).
 - Asymptomatic and not immunocompromised
 - At least seven days have passed since the day of the first positive and negative viral test obtained at least 48 hours before return to work (if antigen test used to test at day five post symptom onset and 48 hours before return to work).
 - Severe or critical illness and not immunocompromised
 - At least 10 to 20 days have passed since symptom onset, no fever within the previous 24 hours, symptoms improving, may also include test-based strategy.
 - Moderately or severely immunocompromised
 - Consultation with ID physician in addition to <u>test-based strategy</u>.



- Symptomatic residents under evaluation for COVID-19
 - Utilize transmission-based precautions until COVID-19 is ruled out
 - Single negative PCR test
 - Negative antigen test confirmed by negative PCR test or second negative antigen test at least 48 hours after first negative test
- Asymptomatic residents after exposure to someone with COVID-19
 - In general, precautions not required, resident should wear source control until test results negative (3 tests, days 1,3,5 post exposure)
 - Consider empiric precautions if resident cannot be tested or wear source control, immunocompromised, residing on unit with others who are immunocompromised, residing on unit with ongoing COVID-19 transmission
 - Precautions can be discontinued 7 days after exposure if no symptoms develop and viral testing remains negative
 - If viral testing is not performed, discontinue precautions after day 10 following the exposure if symptoms do not develop (exposure date = day 0)



Reducing Level of Harm

Does the facility have access to rapidly identify and diagnose the illness when suspected?

- Perform SARS-CoV-2 Viral testing for:
 - Anyone with symptoms regardless of vaccination status
 - Residents who had close contact with someone with COVID-19 using a series of three tests (at one, three-, and five-days post-exposure)
 - Anytime the facility experiences a new case of COVID-19 or other respiratory illness

What <u>treatments</u> or post exposure prophylaxis (PEP) are available?

– What is the process for ordering, receiving and administering treatment or PEP so there is no delay?



Mitigating the Impact on Care

Develop and review policies and procedures:

- <u>Staffing plans</u>
- Cohorting and quarantine plans
- Activities and dining plans
- Visitation plans (including screening, alternative formats, etc.)



Improving the Readiness to Prevent

- Review policies and procedures regularly
- Receive alerts from CDC on updates to guidelines
- Receive Health Alert Network notifications from the health department to understand new or changing threats in your area
- Stay connected with the GDPH and continue to report new positive cases
- Exercise policies and procedures
- Debrief after the event



QUESTION ANSWER

Questions?



Alliant Health Solutions Resources

Image: Second	BALLIANT HEALTH SOLUTIONS	Home Start Here Browse by Topic	Events Library of Resources Q Search				
HEALTH SOLUTIONS GEORGIA	Infection Control Resources						
GA STR₹KE & SUPPORT TEAM Join us for the Georgia Department of Public Health Strike (& Support) Team Office Hours. These sessions will consist of a regularly scheduled monthly webinar for skilled nursing facilities (SNFs) as well as SNF medical directors. Office hours are your opportunity to come and learn, share, vent and more! Each month we will have updates on infection prevention, clinical protocols and ideas for new tools and resources. This is your chance is to access subject matter experts on infection control and clinical practice in long term care. Come prepared to pose your questions to subject matter experts and learn from your peers about their best practices and their barriers.	Sepsis HOIC Sepsis Gap Assessment and Action Steps HOIC Sepsis: Spot the Signs Magnet HOIC Sepsis Provider Engagement AO_Sepsis-ZoneTool Recognition and Management of Severe Sepsis and Septic Shock	Catheter Associated Urinary Tract Infection (CAUTI) CAUTI Gap Assessment Tool Urinary Catheter Quick Observation Tool CDC-HICPAC Guideline for Prevention of CAUTI 2009 AHRQ Toolkit for Reducing CAUTI in Hospitals CDC TAP CAUTI Implementation Guide	Hand Hygiene Handwash the FROG Way – Badges – English Handwash the FROG Way – Badges – Spanish Handwash the FROG Way – Poster – English Handwash the FROG Way – Poster – Spanish Frequently Asked Questions – Alcohol Based Hand Rub				
	SHOW MORE	SHOW MORE Clostridioides Difficile Infection (C. difficile)	Antibiotic Stewardship				
Strike & Support Team Office Hours	Joining the Alliant Health Solutions NHSN Group Instructions for Submitting C. difficile Data Into NHSN 5-Step Enroliment for Long-term Care Facilities CDC's National Healthcare Safety Network (NHSN) NHSN Enroliment/ LAN Event Presentation	C.difficile Training Nursing Home Training Sessions Introduction Nursing Home C.difficile Infection	Antibiotic Stewardship Basics A Field Guide to Antibiotic Stewardship in Outpatient Settings Physician Commitment Letter Be Antibiotics Aware Taking Your Antibiotics				
 <u>Click here</u> to register - November 18, 2022 at 11 a.m. ET <u>Click here</u> to register - December 16, 2022 at 11 a.m. ET <u>Office Hours for Non-SNF:</u> <u>Click here</u> to register - November 18, 2022 at 1 p.m. ET <u>Click here</u> to register - December 16, 2022 at 1 p.m. ET <u>Bite Sized Learning:</u> 	Training Options for Infection Control Training In Nursing Homes Elyer	COVID-19 Invest in Trust (AHRQ Resource for CNA COVID-19 Vaccines) Nursing Home Staff and Visitor Screening Toolkit – PDF Nursing Home Staff and Visitor Screening Toolkit – Excel	SHOW MORE				

https://quality.allianthealth.org/topic/infection-control/



Thank you! Consult with the DPH Team! We are here to help!

State Region/Districts	Contact Information						
North (Rome, Dalton, Gainesville, Athens) Districts 1-1, 1-2, 2, 10	<u>Sue.bunnell@dph.ga.gov (404-967-0582)</u>						
Atlanta Metro (Cobb-Douglas, Fulton, Clayton, Lawrenceville, DeKalb, LaGrange) Districts 3-1, 3-2, 3-3, 3-4, 3-5, 4	<u>Teresa.Fox@dph.ga.gov (256-293-9994)</u> <u>Renee.Miller@dph.ga.gov (678-357-4797)</u>						
Central (Dublin, Macon, Augusta, & Columbus) Districts 5-1, 5-2, 6, 7	<u>Theresa.Metro-Lewis@dph.ga.gov (404-967-0589)</u> Karen.Williams13@dph.ga.gov (404-596-1732)						
Southwest (Albany, Valdosta) Districts 8-1, 8-2	<u>Connie.Stanfill1@dph.ga.gov (404-596-1940)</u>						
Southeast (Savannah, Waycross) Districts 9-1, 9-2	Lynn.Reynolds@dph.ga.gov (804-514-8756)						
Backup/Nights/Weekends	Joanna.Wagner@dph.ga.gov (404-430-6316)						



Thank You for Your Time! Contact the AHS Patient Safety Team <u>Patientsafety@allianthealth.org</u>



Amy Ward, MS, BSN, RN, CIC Patient Safety Manager <u>Amy.Ward@AlliantHealth.org</u> 678.527.3653



Paula St. Hill, MPH, A-IPC Technical Advisor, Infection Prevention <u>Paula.StHill@AlliantHealth.org</u> 678.527.3619



Donald Chitanda, MPH, CIC Technical Advisor, Infection Prevention <u>Donald.Chitanda@AlliantHealth.org</u> 678.527.3651



Erica Umeakunne, MSN, MPH, APRN, CIC Infection Prevention Specialist <u>Erica.Umeakunne@AlliantHealth.org</u>





SNF and Medical Directors Office Hours:

September 15, 2023 | 11 a.m. ET

ALF and PCH August 25, 2023 | 11 a.m. ET September 22, 2023 | 11 a.m. ET



- Georgia Department of Public Health
- University of Georgia





UNIVERSITY OF GEORGIA

Making Health Care Better





This material was prepared by Alliant Health Solutions, under contract with the Georgia Department of Public Health as made possible through the American Rescue Plan Act of 2021. GA DPH--4286-08/14/23

quality.allianthealth.org